Monday, April 28, 2025

Latest

Tag: Mind Medicine

MindMed Activist Investor Moves To Take Control Of Board

MindMed (NASDAQ: MNMD) has seen its activist investor file a preliminary proxy statement for its proposed set of directors after the firm indicated last year it intended to work to take control of the company. The activist investor, FCM MM Holdings, is ran by a former co-founder of MindMed, Dr Scott Freeman.

Describing itself as “one of MindMed’s largest investors,” the firm has just a 3.5% stake in the company, yet is attempting to exert control. FCM proposed a total of four directors for the firms board, including Dr Scott Freeman, co-founder of MindMed and former Chief Medical Officer, Dr Farzin Farzaneh, a professor of molecular medicine at King’s College London, Vivek Jain, a venture capitalist, and Alexander Wodka, a former partner at Crowe.

In announcing that the filing has been made, FCM highlighted that MindMed has seen its shares decline 89% over the past year, despite its peer group falling on average 62%.

The firm also addressed recent comments by MindMed wherein the company referred to FCM as not having paid a “control premium,” which FCM claims is “simply mendacious,” given the fact that they are not seeking a buy out (they just want control instead). FCM claims that they are simply looking to repair operational challenges and restore shareholder value.

“Since 2021, I have been proactively engaging the Board about the delays in the MM-110 and MM-120 programs. Unfortunately, these entreaties were ignored, and subsequently, management botched the MM-110 program while the MM-120 program is over a year behind schedule due to a myriad of operational failures. As a result, I believe the only path forward for MindMed is an immediate reconstitution of the Board,” commented Freeman.

MindMed last traded at $3.81 on the Nasdaq.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Proxy Fight Looms For MindMed Vs. Co-Founder

April 19, 2023, 09:43:00 AM

MindMed Expects Results For Anxiety, ADHD Trials By Late 2023

January 9, 2023, 10:40:35 AM

Activist Investor Calls For MindMed CEO’s Termination Due To Alleged Fraudulent Acts

November 3, 2022, 03:10:00 PM

Mindmed: Canaccord Calls Financing “Puzzling And Unusual”

October 1, 2022, 01:04:00 PM

Mind Medicine Prices $30 Million Offering At 30% Discount To Market

September 28, 2022, 09:28:04 AM

MindMed Starts Dosing Patients In Phase 1 Clinical Study On MDMA-Like Substances

September 21, 2022, 11:23:00 AM

MindMed Sees Positive Results For Its LSD Treatment For Anxiety Disorders Published In Peer-Reviewed Journal

September 8, 2022, 05:03:00 PM

Mindmed Completes 15-To-1 Reverse Split To Maintain Nasdaq Compliance

August 29, 2022, 08:21:39 AM

Mind Medicine Begins Phase 2B Study On Treating Generalized Anxiety Disorder With LSD Variant

August 25, 2022, 08:50:31 AM

MindMed Declares US$17.0 Million Net Loss, US$105.7 Million Cash Balance For Q2 2022

August 12, 2022, 08:20:03 AM

Mind Medicine Sees Co-Founder Become An Activist Shareholder Demanding Changes

August 11, 2022, 08:41:59 AM

Mindmed To Conduct 15-To-1 Reverse Split To Meet Nasdaq Listing Requirements

August 5, 2022, 08:42:02 AM
Video Articles

Bell Q3 Earnings: Massive Impairments. Guidance Cuts. A Mess.

Alamos Gold Q3: Record Revenue & Production Amid Rising Costs

The Junior Mining Market Is Back

Recommended

Germany Looks To Modernize Military Recruitment But Stops Short of Conscription

First Majestic Silver Posts Topline Revenue Of $146.1 Million In Q3 2024